Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly ...
Libris Innovations, the for-profit subsidiary of the Indiana Biosciences Research Institute (IBRI), is pleased to announce ...
Hyundai Bioscience (KOSDAQ: 048410) today announced a groundbreaking roadmap to combat global viral epidemics, officially declaring its entry into Phase 2 clinical trials in the United States.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...
Atara Biotherapeutics in Thousand Oaks is seeking approval for a new cancer treatment. It's a life and death matter for ...
Extreme Networks, Inc. (NASDAQ:EXTR) Q2 2026 Earnings Call Transcript January 28, 2026 Extreme Networks, Inc. beats earnings ...
Consistent with strategy, Servier remains confident in its ability to achieve global annual revenues of €10 billion by 2030 and an EBITDA margin of at least 30%.
Research into cancer and neurodegenerative disease hangs in the balance.
With Waters stockholders voting to issue shares, the companies are targeting a Feb. 9 close date for the deal.
XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud ...
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results